Inventor · disambiguated record
Hubert Kettenberger
Also filed as: KETTENBERGER HUBERT
28 granted patents·25 pending applications·224 citations·filing 2009–2024
96Inventor score
Top patents by PatentIndex Score
53 records- 0197US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0295US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 0394US8945552B2Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2011·Granted Feb 3, 2015·36 cites·12 claims
- 0494US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 0592US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 0691US10822402B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Nov 3, 2020·4 cites·12 claims
- 0791US10611825B2Monovalent antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted Apr 7, 2020·6 cites·8 claims
- 0891US9982036B2Dual FC antigen binding proteinsBOSSENMAIER BIRGIT·Filed 2012·Granted May 29, 2018·12 cites·3 claims
- 0991US9714292B2Bispecific antibodies against human TWEAK and human IL17 and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Jul 25, 2017·21 cites·14 claims
- 1085US9862763B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Jan 9, 2018·4 cites·13 claims
- 1184US12297263B2Humanized anti-Tau(PS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted May 13, 2025·0 cites·6 claims
- 1284US2023399391A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1383US10730938B2Bispecific antibodies and methods of use in ophthalmologyHOFFMANN LA ROCHE·Filed 2017·Granted Aug 4, 2020·3 cites·13 claims
- 1482US11739142B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Granted Aug 29, 2023·1 cites·2 claims
- 1582US9562091B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2014·Granted Feb 7, 2017·4 cites·10 claims
- 1682US9150641B2Sequence dependent aggregationKETTENBERGER HUBERT·Filed 2010·Granted Oct 6, 2015·8 cites·6 claims
- 1782US2025376523A1Humanized anti-human cd19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1881US11668722B2Antibody selection methodHOFFMANN LA ROCHE·Filed 2019·Granted Jun 6, 2023·1 cites·7 claims
- 1980US10465000B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·2 cites·6 claims
- 2080US2024077495A1Spr-based bridging assay format for determining the biological activity of multivalent, multispecific moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2179US2024101657A1Antibody that binds to vegf and il-1beta and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2277US12103967B2Bispecific anti-CCL2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Granted Oct 1, 2024·0 cites·27 claims
- 2377US10538585B2Anti-ANG2 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Jan 21, 2020·2 cites·6 claims
- 2476US12215152B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Feb 4, 2025·0 cites·8 claims
- 2573US12487245B2Antibody selection methodHOFFMANN LA ROCHE·Filed 2023·Granted Dec 2, 2025·0 cites·7 claims
- 2673US11866490B2Antibody that binds to VEGF and IL-1beta and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Jan 9, 2024·0 cites·36 claims
- 2772US11572404B2Humanized anti-Tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Feb 7, 2023·0 cites·6 claims
- 2872US2021047394A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2972US2024083993A1Bispecific anti-ccl2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3071US11130804B2Antibody that binds to VEGF and IL-1beta and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Sep 28, 2021·0 cites·28 claims
- 3171US2023279090A1Non-covalent protein-hyaluronan conjugates for long-acting ocular deliveryGENENTECH INC·Filed 2023·Application pending·0 cites
- 3271US2023256107A1Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeuticsGENENTECH INC·Filed 2023·Application pending·0 cites
- 3369US2021199666A1Spr-based bridging assay format for determining the biological activity of multivalent, multispecific moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3465US2020223912A1Humanized anti-tau(ps422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3565US2023129340A1Method for producing multispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3662US10793621B2Nucleic acid encoding dual Fc antigen binding proteinsHOFFMANN LA ROCHE·Filed 2018·Granted Oct 6, 2020·0 cites·5 claims
- 3761US2017369566A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3860US12461109B2Vitro prediction of in vivo half-lifeHOFFMANN LA ROCHE·Filed 2021·Granted Nov 4, 2025·0 cites·4 claims
- 3960US2017003295A1Spr-based bridging assay format for determining the biological activity of multivalent, multispecific moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4059US2015191535A1Bispecific, bivalent anti-vegf/anti-ang2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 4158US2023105324A1Antibody that binds to vegf and pdgf-b and methods of useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4256US2020216553A1Method for producing multispecific antibodiesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4354US2022073593A1Modification of Antibody FcRn bindingHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4452US10047162B2Sequence dependent aggregationHOFFMANN LA ROCHE·Filed 2015·Granted Aug 14, 2018·0 cites·5 claims
- 4552US2020066372A1Method for improving antibody stabilityHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4651US2017240626A1Bispecific, bivalent anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4749US2012237507A1Monovalent Antigen Binding ProteinsBOSSENMAIER BIRGIT·Filed 2012·Application pending·0 cites
- 4847US2015250725A1Method for producing a lipid particle, the lipid particle itself and its useHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 4946US10418126B2Method for improving antibody stabilityHOFFMANN LA ROCHE·Filed 2016·Granted Sep 17, 2019·0 cites·6 claims
- 5046US2017211876A1Method for selecting antibodies with modified fcrn interactionHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →